Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4A11 | Q02928 | 5/20 | 0.45 |
| ▸ | CYP4F2 | P78329 | 4/20 | 0.45 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 2/20 | 0.36 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.35 |
| ▸ | CNR1 | P21554 | 6/20 | 0.34 |
| ▸ | CNR2 | P34972 | 5/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20032506 | 1.00 | CYP4A11 (0.45) | CYP4A11CYP4F2TNKS2PPARAGPR84 | |
| SCHEMBL20032520 | 0.77 | CNR2 (0.42) | CNR1CNR2 | |
| SCHEMBL20032236 | 0.77 | KCNN4 (0.38) | CNR1CNR2 | |
| SCHEMBL20032436 | 0.77 | KCNN4 (0.38) | CNR1CNR2 | |
| SCHEMBL21423155 | 0.76 | NOTUM (0.36) | CNR1CNR2 | |
| SCHEMBL8880437 | 0.74 | CYP4A11 (0.54) | CYP4A11CYP4F2PPARACA2 | |
| SCHEMBL11509018 | 0.73 | PTPRB (0.47) | CA2 | |
| SCHEMBL1878357 | 0.72 | CA2 (0.47) | CYP4A11CYP4F2TNKS2GPR84CA2 | |
| SCHEMBL14290225 | 0.72 | PTPRB (0.46) | CYP4A11CYP4F2 | |
| SCHEMBL5198639 | 0.71 | RIPK1 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3519423-B1 | ENDOSOMOLYTIC AGENTS FOR GENE THERAPY | UCB Biopharma SRL (BE) | 2021-04-07 | — | — | EP | disclosed |
| US-10842884-B2 | Endosomolytic agents for gene therapy | UCB Biopharma SRL (BE) | 2020-11-24 | — | — | US | disclosed |
| US-20190298859-A1 | Endosomolytic Agents for Gene Therapy | UCB BIOPHARMA SRL (UCB BIOPHARMA SOCIETE A RESPONSABILITE LIMITEE) (BE) | 2019-10-03 | — | — | US | disclosed |
| WO-2018060280-A1 | ENDOSOMOLYTIC AGENTS FOR GENE THERAPY | UCB BIOPHARMA SPRL (BE) | 2018-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10842884-B2 | Endosomolytic agents for gene therapy | YARS1, ARSA, RPS6 | CYP4A11 3798/4885CYP4F2 3745/4885TNKS2 4187/4885 |
| US-20190298859-A1 | Endosomolytic Agents for Gene Therapy | YARS1, ARSA, RPS6 | CYP4A11 3798/4885CYP4F2 3745/4885TNKS2 4187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.